IL17A and tuberculosis: Conversely, the unique gut microbiome features with high abundance of SCFA producers (Bacteroides and Alistepes) in current pDM patients with LTBI may enhance TB susceptibility by suppressing B cells and CD4+ and CD8+ lymphocytes, reducing the production of TB-induced IFN-γ and IL-17, increasing Foxp1 expression [14, 28, 30, 31] and elevating the number of T regulatory cells in peripheral blood [29].